{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:44:53Z","timestamp":1747183493713,"version":"3.40.5"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T00:00:00Z","timestamp":1679184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Low\u2010dose rivaroxaban has been indicated for the management of atherosclerotic cardiovascular disease (ASCVD) after recent (2019\u20102020) updates to European guidelines. We aimed to describe prescription trends of low\u2010dose rivaroxaban in ASCVD patients over the period 2015\u20102022 in two European countries, to compare the trends before and after guideline changes, and to determine the characteristics of users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a cross\u2010sectional interrupted time series analysis, utilization of low\u2010dose rivaroxaban (2.5\u2009mg, twice daily) was measured in Clinical Practice Research Datalink Aurum (United Kingdom [UK]) and the PHARMO Database Network (the Netherlands) from 1 January 2015 to 28 February 2022 in patients with an ASCVD diagnosis. Incidence rates (IRs) and incidence rate ratios (IRRs) of new use (within 182\u2009days) compared to the reference period, 2015\u20102018, were calculated. Age, sex and comorbidities of users were compared to those of nonusers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the UK, from 721\u2009271 eligible subjects the IR of new use of low\u2010dose rivaroxaban in the period 2015\u20102018, before guideline changes, was 12.4 per 100\u2009000 person\u2010years and after guideline changes in 2020\u20102022 was 124.0 (IRR 10.0, 95% confidence interval [CI] 8.5, 11.8). In the Netherlands from 394\u2009851 subjects, the IR in 2015\u20102018 was 2.4 per 100\u2009000 person\u2010years and in 2020 was 16.3 (IRR 6.7, 95% CI 4.0, 11.4). Users were younger (UK mean difference [MD] \u22126.1\u00a0years, Netherlands \u22122.4\u00a0years; <jats:italic>P<\/jats:italic>\u00a0&lt;\u2009.05) and more likely to be male (UK difference 11.5%, Netherlands 13.4%; <jats:italic>P<\/jats:italic>\u00a0&lt;\u2009.001) than nonusers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There was a statistically significant increase in the use of low\u2010dose rivaroxaban for the management of ASCVD after guideline changes in the UK and the Netherlands. There were international differences, but low\u2010dose rivaroxaban has not been put into widespread practice.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15708","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T03:13:05Z","timestamp":1678331585000},"page":"2263-2271","source":"Crossref","is-referenced-by-count":0,"title":["Prescribing of low\u2010dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1677-6025","authenticated-orcid":false,"given":"Nicholas B.","family":"Hunt","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romin","family":"Pajouheshnia","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Salih","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Department of General Practice, Julius Center for Health Sciences and Primary Care University Medical Centre Utrecht  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7452-0477","authenticated-orcid":false,"given":"Patrick C.","family":"Souverein","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marloes T.","family":"Bazelier","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf H.","family":"Klungel","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-9684","authenticated-orcid":false,"given":"Helga","family":"Gardarsdottir","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"},{"name":"Department of Clinical Pharmacy University Medical Centre Utrecht  Utrecht The Netherlands"},{"name":"Department of Pharmaceutical Sciences, School of Health Sciences University of Iceland  Reykjavik Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,19]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Cardiovascular diseases (CVDs) [Internet]. [cited 2022 Jun 13]. Available from:https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu505"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1322"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735\u20101097(02)02776\u20106"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709118"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvac023"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239\u2010020\u201002114\u20107"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.608247","article-title":"Low dose rivaroxaban for atherosclerotic cardiovascular diseases: a systematic review and meta\u2010analysis","volume":"11","author":"Chen C","year":"2021","journal-title":"Front Pharmacol"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvab043"},{"key":"e_1_2_12_14_1","unstructured":"NICE.Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease [Internet].2019[cited 2021 Jul 12]. Available from:https:\/\/www.nice.org.uk\/guidance\/ta607"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa575"},{"key":"e_1_2_12_17_1","unstructured":"Zorginstituut Nederland.rivaroxaban Xarelto\u00ae preventie van atherotrombotische complicaties bij volwassen pati\u00ebnten met CHZ of PAV met een hoog risico op ischemische events.2019."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy394"},{"key":"e_1_2_12_20_1","unstructured":"PHARMO Database Network [Internet]. [cited 2022 Apr 14]. Available from:http:\/\/pharmo.nl\/PHARMO-database-network\/"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017310"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15580"},{"issue":"1","key":"e_1_2_12_23_1","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch E","year":"2021","journal-title":"JAMA Cardiol"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000052"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx658"},{"issue":"12","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024655","article-title":"Sex\u2010based differences in outcomes following peripheral artery revascularization: insights from VOYAGER PAD","volume":"11","author":"Hess CN","year":"2022","journal-title":"J Am Hear Assoc Cardiovasc Cerebrovasc Dis"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suaa128"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz005"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14450"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy347"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz372"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvab050"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-318758"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2078100"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18\u20103079"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15708","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T03:52:52Z","timestamp":1714449172000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,19]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1111\/bcp.15708"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15708","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2023,3,19]]}}}